As of May 22
| -0.0198 / -3.59%|
The 1 analysts offering 12-month price forecasts for KaloBios Pharmaceuticals Inc have a median target of 8.00, with a high estimate of 8.00 and a low estimate of 8.00. The median estimate represents a +1,403.76% increase from the last price of 0.53.
The current consensus among 2 polled investment analysts is to Buy stock in KaloBios Pharmaceuticals Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.